Sandoz agreed to pay $450 million to resolve antitrust litigation with 43 US states and territories over alleged anti-competitive conduct in the generic medicines market. The Swiss drugmaker's US subsidiary will pay $400 million over seven years starting in 2027, plus about $50 million to states that settled earlier. Neither settlement includes an admission of wrongdoing.
Sandoz agreed to pay $450 million to resolve antitrust claims brought by 43 US states over alleged anti-competitive conduct in the generic medicines market.
"These settlements do not affect full-year 2026 guidance or the Sandoz mid-term outlook," the Swiss drugmaker said Monday.
Under the agreement, Sandoz's US subsidiary will pay $400 million over seven years starting in 2027, with an additional payment of approximately $50 million to states that settled earlier. Neither settlement contains an admission of wrongdoing by Sandoz US, the company said.
The settlement removes a legal overhang for Sandoz, which was spun off from Novartis in 2023. The resolution could set a precedent for similar antitrust actions across the generic pharmaceutical sector, Reuters reported.
The agreement covers 43 US states and territories, resolving litigation that alleged the company engaged in anti-competitive conduct in the market for generic medicines. Sandoz did not disclose which states were party to the earlier settlements that triggered the additional $50 million payment.
The settlement comes as generic drugmakers face heightened antitrust scrutiny from state attorneys general over pricing and market allocation practices. Sandoz, one of the world's largest generic drugmakers alongside Teva Pharmaceutical and Viatris, competes in a market where consolidation and pricing pressure have reshaped the industry.
For Sandoz shareholders, the settlement removes a multi-year legal uncertainty while spreading the $450 million liability across seven years, limiting near-term cash impact. Investors will watch whether similar antitrust settlements emerge across the generic drug sector and how the payments affect Sandoz's results when the first installments begin in 2027.
This article is for informational purposes only and does not constitute investment advice.
